Ichor Biologics is a New York–based biotechnology company developing next-generation technologies for human antibody discovery and immune profiling. Our platform integrates antigen-specific B-cell isolation, engineered ex vivo immune-cell systems, functional antibody screening, and single-cell molecular profiling to connect immune function with antibody sequence. By generating high-resolution, human-relevant data directly from blood, Ichor aims to accelerate therapeutic antibody discovery, biomarker development, and vaccine research across infectious disease, autoimmunity, and cancer. The company is also advancing a pipeline of antibody therapeutics and diagnostics for emerging infectious diseases.